India has approved two more vaccines, Covovax and Corbevax, for emergency use on Tuesday to strengthen its fight against the novel coronavirus.
Who are the makers of the two vaccines?
Covovax is being produced by the Serum Institute of India under licence from Novavax, a U.S.-based biotechnology company while Corbevax is co-developed by Biological E, Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies
How many doses are recommended?
Both Covovax and Corbevax are 2-dose vaccines. The recommended gap by WHO between two doses of Covovax is 21 days. For Corbevax, the gap recommended by experts is 28 days. The Indian govt has however not issued any guidelines yet.
How effective are both vaccines?
Novavax, the developers of Covovax, conducted phase-3 efficacy trials in the USA and UK wherein the efficacy of vaccine is reported to be 90.4 per cent and 86.9 per cent respectively, the statement said.
Biological-E, co-developer of Corbevax, has conducted phase 3 trials in the India but the results have not been published yet.